We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Low Zinc May Indicate Potential Breast-Feeding Problems

By LabMedica International staff writers
Posted on 27 Dec 2015
A new study provides an important step toward identifying breast-fed infants at risk for severe zinc deficiency. More...
Identifying mothers with abnormally low levels of zinc in breast milk may enable to more quickly determine those more likely to have trouble breast-feeding.

The protein ZnT2 transports zinc in specific tissues, including the mammary glands, where zinc is necessary for growth of mammary glands and function of mammary epithelial cells and secretion pathways. In previous studies, Shannon L. Kelleher, associate professor at Penn State University’s College of Medicine (Hershey, PA, USA) and colleagues found that ZnT2 is critical for secreting zinc into breast milk and women who have ZnT2 mutations have substantially lower milk zinc levels, leading to severe zinc deficiency in exclusively breast-fed infants. Also, ZnT2 deletion in mice altered milk composition and profoundly impaired the ability of mice to successfully nurse their offspring.

Now the researchers have found that ZnT2 genetic variation resulting in either loss or gain of function may be common and in some cases is associated with indicators of poor breast function. Of 54 breast-feeding women, 36% had at least one non-synonymous single nucleotide polymorphism (SNP) in ZnT2 and the genetic variation was associated with abnormal levels of zinc in their breast milk. 12 previously unknown variants of ZnT2 were identified in the participants, and 5 of these variants were statistically associated with abnormal zinc levels in breast milk. "We had no idea that genetic variation in ZnT2 would be so common," said Prof. Kelleher.

Among the 36% of breast-feeding women found to have at least one genetic variant in ZnT2, all had an abnormally low or high level of zinc in breast milk. However, abnormal zinc levels did not automatically imply a problem with ZnT2, indicating that other factors remain to be identified.

The participants were sorted into 4 groups according to breast milk zinc levels. In the group with the lowest zinc levels, researchers identified ZnT2 variants in 79% of the women; in the group with the highest levels, 29% had ZnT2 variants. Importantly, among the subjects with normal milk zinc levels, no variants in ZnT2 were detected.

The researchers also examined the milk for ratio of sodium to potassium (Na/K) as a known indicator of breast dysfunction, including infection and inflammation of the breast. 12% of women had the most common ZnT2 variant, T288S, and had a significantly higher Na/K ratio compared with women with no variation in ZnT2. Another 9% of women with a different, less common ZnT2 variant, D103E, had a higher Na/K ratio than women with no ZnT2 variation, although this was not significant due to the low number of women in the study with this variant.

Together these observations point to ZnT2 variation as a modifier of breast function and zinc levels in breast milk as a potential indicator of deficient lactation. Further research is needed to better understand how genetic variation affects milk zinc levels and breast function.

The study, by Alam S et al., was published in the December 2015 issue of the Journal of Mammary Gland Biology and Neoplasia.

Related Links:

Penn State Hershey College of Medicine 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.